During the evolution of percutaneous coronary intervention (PCI) from balloon angioplasty to bare metal stents (BMS) and subsequently, to 1st and 2nd generation drug-eluting stents (DES), early coronary occlusion (thrombosis, dissection) and late (one-year) restenosis rates have progressively declined [ ]. Although iterations in metallic DES including novel metal alloy composition, reduced strut thickness and improved polymer biocompatibility and/or resorption, have contributed to improved outcomes, concerns regarding incomplete endothelialization, polymer hypersensitivity, neoatherosclerosis and stent fracture persist.